Cargando…

FDA Experience with Medical Countermeasures under the Animal Rule

The Food and Drug Administration issued a final rule in May 2002 to permit the Agency to approve drugs or license biological products on the basis of animal efficacy studies for use in ameliorating or preventing serious or life-threatening conditions caused by exposure to lethal or permanently disab...

Descripción completa

Detalles Bibliográficos
Autor principal:	Aebersold, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3177089/ https://www.ncbi.nlm.nih.gov/pubmed/21991452 http://dx.doi.org/10.1155/2012/507571

Ejemplares similares

Rabbitpox in New Zealand White Rabbits: A Therapeutic Model for Evaluation of Poxvirus Medical Countermeasures Under the FDA Animal Rule
por: Perry, Mark R., et al.
Publicado: (2018)

First vaccine approval under the FDA Animal Rule
por: Beasley, David W C, et al.
Publicado: (2016)

Animal‐to‐Human Dose Translation of Obiltoxaximab for Treatment of Inhalational Anthrax Under the US FDA Animal Rule
por: Nagy, CF, et al.
Publicado: (2016)

Medical Countermeasures for Radiation Exposure and Related Injuries: Characterization of Medicines, FDA-Approval Status and Inclusion into the Strategic National Stockpile
por: Singh, Vijay K., et al.
Publicado: (2015)

Dose Selection in a Pandemic: A Framework Informed by the FDA Animal Rule
por: Wu, Kunyi, et al.
Publicado: (2020)

Medical Countermeasures against Ricin Intoxication
por: Rasetti-Escargueil, Christine, et al.
Publicado: (2023)

ECMO as an emergency medical countermeasure
por: Paul, Subroto, et al.
Publicado: (2014)

Zika Virus: Medical Countermeasure Development Challenges
por: Malone, Robert W., et al.
Publicado: (2016)

Design Strategies for Cellular Nanosponges as Medical Countermeasures
por: Wang, Shuyan, et al.
Publicado: (2023)

Medical countermeasures for unwanted CBRN exposures: part II radiological and nuclear threats with review of recent countermeasure patents
por: Singh, Vijay K., et al.
Publicado: (2016)

Understanding the new FDA pregnancy and lactation labeling rules()
por: Blattner, Collin M., et al.
Publicado: (2016)

The FDA's Final Rule on Expedited Safety Reporting: Statistical Considerations
por: Wittes, Janet, et al.
Publicado: (2015)

Investigators’ Experience With Expedited Safety Reports Prior to the FDA’s Final IND Safety Reporting Rule
por: Kramer, Judith M., et al.
Publicado: (2014)

Impact of recent FDA ruling on testosterone replacement therapy (TRT)
por: Metzger, Sarita O., et al.
Publicado: (2016)

The proposed rule of the FDA banning menthol as a characterizing flavor
por: Romeo-Stuppy, Kelsey
Publicado: (2022)

Entamoeba histolytica under Oxidative Stress: What Countermeasure Mechanisms Are in Place?
por: Pineda, Erika, et al.
Publicado: (2017)

Meeting the challenges of medical countermeasure development
por: Maher, Carmen, et al.
Publicado: (2012)

Antioxidant Tocols as Radiation Countermeasures (Challenges to be Addressed to Use Tocols as Radiation Countermeasures in Humans)
por: Nukala, Ujwani, et al.
Publicado: (2018)

Medical countermeasures against henipaviruses: a review and public health perspective
por: Gómez Román, Raúl, et al.
Publicado: (2022)

Additively manufactured medical products – the FDA perspective
por: Di Prima, Matthew, et al.
Publicado: (2016)

FDA-approved medications that impair human spermatogenesis
por: Ding, Jiayi, et al.
Publicado: (2016)

Effect of COVID-19 on animal breeding development in China and its countermeasures
por: Ding, Yaqiong, et al.
Publicado: (2021)

Editorial: Recent advances in radiation medical countermeasures
por: Tichy, Ales, et al.
Publicado: (2022)

Gadolinium in Medical Imaging—Usefulness, Toxic Reactions and Possible Countermeasures—A Review
por: Blomqvist, Lennart, et al.
Publicado: (2022)

Autophagy, antiviral immunity, and viral countermeasures
por: Shoji-Kawata, Sanae, et al.
Publicado: (2009)

On-orbit sleep problems of astronauts and countermeasures
por: Wu, Bin, et al.
Publicado: (2018)

Radioprotective countermeasures for radiation injury (Review)
por: Liu, Lianchang, et al.
Publicado: (2023)

Overview and countermeasures of cancer burden in China
por: Wang, Yian, et al.
Publicado: (2023)

The Need for Continued Development of Ricin Countermeasures
por: Reisler, Ronald B., et al.
Publicado: (2012)

Medical Education under Home Rule
Publicado: (1912)

Network radar countermeasure systems: integrating radar and radar countermeasures
por: Jiang, Qiuxi
Publicado: (2016)

FDA oversight of medical devices
por: Hill, Matthew W, et al.
Publicado: (2012)

Toxins as biological weapons for terror—characteristics, challenges and medical countermeasures: a mini-review
por: Berger, Tamar, et al.
Publicado: (2016)

Nutritional and Behavioral Countermeasures as Medication Approaches to Relieve Motion Sickness: A Comprehensive Review
por: Rahimzadeh, Ghazal, et al.
Publicado: (2023)

An Interagency Collaboration to Facilitate Development of Filovirus Medical Countermeasures
por: Kilgore, Nicole, et al.
Publicado: (2012)

Strengthening the US Medical Countermeasure Enterprise for Biological Threats
por: Ravi, Sanjana, et al.
Publicado: (2017)

Innovative approaches to COVID-19 medical countermeasure development
por: Harris, Gavin H, et al.
Publicado: (2023)

Psychosomatic problems and countermeasures in Japanese children and adolescents
por: Tanaka, Hidetaka, et al.
Publicado: (2012)

Activation of the Antiviral Kinase PKR and Viral Countermeasures
por: Dauber, Bianca, et al.
Publicado: (2009)

Radiation countermeasure agents: an update (2011 – 2014)
por: Singh, Vijay K, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_o0nse741f0v0nurmsuohe4ci1m